Nom du produit:tert-Butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate
IUPAC Name:tert-butyl 4-(1-hydroxypropan-2-yl)piperazine-1-carboxylate
- CAS：900535-75-3
- Formule moléculaire：C12H24N2O3
- Pureté：95%+
- Numéro de catalogue：CM335388
- Poids moléculaire：244.33
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:900535-75-3
- Formule moléculaire:C12H24N2O3
- Point de fusion:-
- Code SMILES:O=C(N1CCN(C(C)CO)CC1)OC(C)(C)C
- Densité:
- Numéro de catalogue:CM335388
- Poids moléculaire:244.33
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Column Infos
- Ziftomenib
- Kura Oncology reported preliminary clinical data from the first 20 patients in KOMET-007, a Phase 1 dose-escalation trial of the Company's potent and selective menin inhibitor, ziftomenib, in combination with standards of care, including cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza), in patients with NPM1-mutant (NPM1-m) and KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients with high unmet need. In preclinical models, ziftomenib inhibits the KMT2A/MLL protein complex and exhibits downstream effects on HOXA9/MEIS1 expression and potent anti-leukemic activity in genetically defined preclinical models of AML. Ziftomenib has received Orphan Drug Designation from the FDA for the treatment of AML.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
